PFE

Pfizer offers a higher dividend yield of 5.8% compared to Bristol Myers Squibb's 4.3%, making it more attractive for income investors. However, Bristol Myers Squibb maintains a safer dividend with a 55% payout ratio versus Pfizer's over 100% payout ratio.

Both pharma companies face patent cliffs but have growth prospects. The article suggests Pfizer is better for maximizing income, while Bristol Myers Squibb may deliver higher total returns due to lower execution risk.

Bristol Myers Squibb demonstrates steadier year-over-year revenue growth with consistent upward trends, while Pfizer shows higher absolute revenue but experienced recent fluctuations and contraction periods. BMY's revenue is projected to edge up 3% to $49.9 billion with net income rising over 40%, while PFE's revenue is expected to slump slightly to $62.2 billion despite net income gains. Based on revenue trends alone, Bristol Myers Squibb appears to be on a better trajectory, though both companies show positive comparable quarter-over-quarter growth.

Pfizer (PFE) closed at $30.11, up 2.28%, outperforming the S&P 500. The stock has gained 6.13% over the past month.

However, the company faces headwinds with expected Q3 2026 EPS declining 17.24% year-over-year and full-year earnings projected down 8.39%. Pfizer holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 9.99, trading at a discount to its industry average. The Large Cap Pharmaceuticals industry ranks in the bottom 12% of sectors.

Pfizer has been trending on Zacks.com with shares returning +6.1% over the past month, outperforming the S&P 500's +0.7% gain. However, the company faces headwinds with earnings expected to decline 8.4% year-over-year for the current fiscal year and revenue projected to remain flat. Despite beating consensus estimates in recent quarters and trading at a discount to peers, Pfizer received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.

Pfizer stock has gained 18% this year amid a potential rotation from tech to healthcare stocks. The company offers an attractive 5.8% dividend yield and trades at a forward P/E multiple of around 10, suggesting significant undervaluation despite a high trailing P/E of 37 due to restructuring charges. Analysts believe the stock has substantial upside potential as the market recognizes its value.

Pfizer will report Q3 2026 earnings on November 3, with focus on non-oncology segments. Eliquis demand is expected to boost Primary Care sales, while COVID-19 vaccine and Paxlovid revenues will decline. Specialty Care segment may see Vyndaqel growth offset by declines in Xeljanz and Enbrel due to competitive pressures.

The article examines five high-yield dividend stocks with yields ranging from 5.88% to 16.72%. Featured stocks include Altria Group (5.93% yield, 57-year dividend streak), AGNC Investment (16.72% yield but at risk from rising rates), Energy Transfer (6.57% yield, 19 consecutive quarters of increases), Pfizer (6.06% yield, 352 consecutive quarterly dividends), and Realty Income (5.88% yield, 116 consecutive quarters of increases). While these stocks offer steady income, investors should be aware of sector-specific risks including interest rate sensitivity and commercial real estate headwinds.

AbbVie, a Dividend King with 53 consecutive years of dividend increases, would require 723 shares (approximately $206,358) to generate $5,000 in annual dividends at its current price. Despite a modest 2.4% forward yield, the pharmaceutical giant's strong portfolio of blockbuster drugs, low P/E ratio of 16, and 93% stock rally over three years make it an attractive long-term income investment, even compared to higher-yielding alternatives like Pfizer.

Pfizer declared its 352nd consecutive quarterly dividend with a 5.9% yield, significantly higher than the S&P 500 average of 1%. While the company faces patent cliffs on major drugs like Eliquis and Xeljanz this year, it maintains a robust pipeline focused on cancer treatments and generated $11 billion in free cash flow over the past four quarters, exceeding dividend payments. Management remains committed to maintaining and growing the dividend, though investors must have confidence in the company's ability to replace expiring patents with new pipeline drugs.

Six major blue-chip stocks—Nike, Goldman Sachs, Intel, Disney, Pfizer, and Home Depot—are trading at least 20% below their all-time highs despite a strong bull market. The article analyzes each stock to determine whether they represent bargains or value traps, considering factors like valuation metrics, competitive pressures, and market sentiment.

Verizon Communications and Pfizer are highlighted as attractive high-yield dividend stocks for income investors. Verizon offers a 6.5% forward dividend yield backed by strong subscriber growth and improved customer retention, while Pfizer provides a 6.1% yield with a 352-consecutive-quarter dividend history and growth potential from its oncology pipeline and 96 research programs.

AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

Pfizer (PFE) closed at $29.21, up 2.96% on the day, outperforming the S&P 500. However, the company faces headwinds with projected Q3 EPS declining 17.24% year-over-year and full-year earnings expected to drop 8.39%.

The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 9.63, trading at a discount to industry averages. Earnings are scheduled for November 3, 2026.

Pfizer's stock has moved above its 50-day moving average, supported by new drug launches and acquisitions. While the company faces significant headwinds from declining COVID-19 product sales and an upcoming patent cliff, its diversified portfolio, strong oncology pipeline, obesity drug berobenatide program, attractive 6.1% dividend yield, and $9.7 billion in cost savings through 2029 provide support. Analysts recommend holding the stock at current levels given its inexpensive valuation relative to peers.

The article explains how to identify stocks with positive earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) filter, which compares the most recent analyst estimates against consensus estimates. The strategy combining positive ESP with Zacks Rank #3 or better has historically resulted in 70% positive earnings surprises and 28.3% average annual returns. Johnson & Johnson and Pfizer are highlighted as medical stocks with positive ESPs ahead of their upcoming earnings reports.

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

Zacks Research Daily features analysis of 16 major stocks including JPMorgan Chase, ASML, and Chevron, plus two microcap stocks. JPMorgan benefits from strong earnings and diversified revenues; ASML faces balanced opportunities and risks from AI demand; Chevron shows strong production growth and cash flow. Additional coverage includes Pfizer, Valero Energy, and Constellation Energy, with mixed outlooks across sectors.

The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories.

Pfizer has been heavily searched on Zacks.com lately. The stock returned +0.6% over the past month, underperforming the S&P 500's +1.3% gain.

Pfizer holds a Zacks Rank #2 (Buy) rating based on earnings estimate revisions and other factors. The company is expected to report declining earnings year-over-year but has consistently beaten consensus estimates in recent quarters. Pfizer trades at a valuation discount to peers with a B grade on the Value Style Score.

The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.